


Introduction

Triple-negative breast cancer (TNBC) is one of the harder forms of breast cancer to treat due to it lacking three receptors that are essential to the targeted therapy used to treat other forms of breast cancer. The Notch pathway is a protein pathway that has been proven essential in both healthy cells, specifically CD8 T-cells, and cancer cell growth and is generally overexpressed in cancer cells, including TNBC. Its prevalence in TNBC subsequently makes it a focus in finding targeted therapies for TNBC. CD8⁺ T-cells are immune cells that eliminate harmful substances, including tumors. The Notch pathway is also known to play a role in T-cell activation, which is necessary for the anti-tumor response in the body. With the non-canonical Notch pathway regulating both mitochondrial metabolism in TNBC cells and T-cell activation in CD8 T-cells, attempting to target this pathway in TNBC cells while not affecting CD8⁺ T-cells is a daunting task.

Objective

The aim of this project is to better understand the role of mitochondrial Notch (non-canonical Notch) in CD8⁺ T-cell metabolism, cell proliferation, and cytotoxic activity.

Methods



Results




Figure 1. Confocal imaging showing the co-localization of Notch-1 and the mitochondria of stimulated (a-CD3/CD28 for 72 hrs) mouse CD8⁺ T-cells.




Figure 2. Western blot analysis to confirm the presence of Notch-1 in mitochondria of CD8⁺ T-cells. CD8⁺ T cells were isolated from C57BL/6 mouse spleen using EasySep CD8⁺ T cell isolation kit (STEMCELL Technologies) and then stimulated with plate bound a-CD3/CD28 for 72 hours. (A) Mitochondrial fractions were purified using a mitochondrial isolation kit (Abcam). Western blot shows the presence of Notch-1 in the mitochondrial fractions. (B) Immunoprecipitation (IP) of mitochondrial fractions with Notch-1 and IgG antibody, followed by Western blot analysis with Notch-1 antibody.




Figure 3A. T-cell proliferation assay demonstrating proliferation levels of CD8 T-cells. Gamma-secretase inhibitor (GSI) (PF-3084014) (10 μM) reduced CD8⁺ T-cells proliferation as measured with carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution by Flow Cytometer.




Figure 3B. T-cell proliferation assay results quantify the percent of proliferation. GSI (PF-3084014) (10 μM) significantly reduced CD8⁺ T-cells proliferation.




Figure 3C. Granzyme B ELISA assay. GSI (PF-3084014) (10 μM) treated CD8⁺ T-cells show reduced cytotoxic activity.

Results




Figure 4A. Glycolytic flux of CD8⁺ T cells as measured by extracellular acidification rate (ECAR) using Seahorse analyzer (Agilent Technologies). Metabolism of activated CD8⁺ T cells is characterized by elevated level of glycolytic flux. GSI (PF-3084014) (10 μM) reduced both the basal and reserve ECAR capacity of CD8⁺ T cells




Figure 4B. Seahorse assay showing cellular energetics as measured by oxygen consumption rate (OCR) vs. ECAR. GSI (PF-3084014) (10 μM) treated CD8⁺ T-cells show reduced metabolic activity as evidenced by the reduction of both OCR and ECAR.

Conclusion

- Notch-1 is present on the mitochondria of CD8⁺ T-cells.
- Our results suggest that in addition to the canonical pathway, non-canonical Notch does play a role in metabolic processes, cell proliferation processes, and cytotoxic activity of CD8⁺ T-cells.
- From these findings, future research will be geared toward determining the specific role Notch-1 plays in these necessary biological processes.